PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 801–900 of 1,009
Zakharia, Y., Bhattacharya, A., & Rustum, Y. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24297 · Cited by 48
“The VHL-dependent regulation of microRNAs in renal cancer.”
BackgroundInfluentialValproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells
Xie, Z., Ago, Y., Okada, N., & Tachibana, M. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.06.014 · Cited by 45
Understanding the tumour micro‐environment communication network from an NOS2/COX2 perspective
Basudhar, D., Bharadwaj, G., Somasundaram, V., Cheng, R. Y. S., Ridnour, L. A., Fujita, M., Lockett, S., Anderson, S. K., McVicar, D. W., & Wink, D. A. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14488 · Cited by 47
“Furthermore, HIF-1α-mediated expression of programmed death-ligand 1 under hypoxia in MDSCs, TAMs and DCs also plays a critical role in T-cell exhaustion (Noman et al., 2014).”
BackgroundFuture of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 49
“These cells derive from hematopoietic stem cells (HSCs) existing in bone marrow, which induce an immature myeloid cell population (59).”
BackgroundPolymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8+ T Cells
Zhang, J., Zhang, L., Yang, Y., Liu, Q., Ma, H., Huang, A., Zhao, Y., Xia, Z., Liu, T., & Wu, G. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.038 · Cited by 53
Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression
Yin, K., Xia, X., Rui, K., Wang, T., & Wang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610104 · Cited by 47
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021) · Cancers · doi:10.3390/cancers13061468 · Cited by 44
“1α (HIF-1α) is one of the mediators of the immune escape, for example, via upregulation of immune checkpoint protein PD-L1 on dendritic cells, macrophages and tumor cells [232,233].”
BackgroundRashid, K., Ahmad, A., Li, L., Liu, M., Cui, Y., & Liu, T. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.004 · Cited by 44
Muraro, E., Fanetti, G., Lupato, V., Giacomarra, V., Steffan, A., Gobitti, C., Vaccher, E., & Franchin, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103424 · Cited by 56
Jiao, H., Weng, B.-S., Yan, S.-S., Lin, Z., Wang, S., Chen, X.-P., Liang, G.-H., Li, X., Zhao, W., Huang, J.-Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02793-3 · Cited by 46
RetractedWang, S., Iyer, R., Han, X., Wei, J., Li, N., Yang, C. H., Zhou, Y., Gao, Q., Zhang, L., Yan, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167728 · Cited by 45
Metabolic rewiring and communication in cancer immunity
Chapman, N. M., & Chi, H. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.001 · Cited by 49
“…However, hypoxia may also trigger immune suppression by impairing intratumoral γδ T cell function, 146 inducing expression of programmed death receptor ligand-1 (PD-L1) on MDSCs (via HIF-1 α ), 147 or promoting Treg cell activation (via HIF-2 α ), 148 thereby limiting intratumoral T cell function.”
BackgroundA review concerning the breast cancer-related tumour microenvironment
Rodríguez-Bejarano, O. H., Parra-López, C., & Patarroyo, M. A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104389 · Cited by 56
Jeon, Y.-K., Park, S.-G., Choi, I.-W., Lee, S.-W., Lee, S. M., & Choi, I. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.098 · Cited by 41
Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
Kapor, S., & Santibanez, J. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132788 · Cited by 44
“Furthermore, MDSCs may induce the suppression of T‐cell activation and apoptosis through cell–cell interaction mediated by immune checkpoint proteins, such as the pro‐ grammed death‐1 (PD‐1) molecule with its cognate ligands PD‐L1 and PD‐L2 [60].”
BackgroundZhu, L., Yu, X., Wang, L., Liu, J., Qu, Z., Zhang, H., Li, L., Chen, J., & Zhou, Q. (2021) · Oncogenesis · doi:10.1038/s41389-021-00335-w · Cited by 46
“In addition, hypoxia-driven inhibitory immune signals, such as PD-L1 on macrophages, DCs, and tumor cells, can become blocked by PDL1 inhibitors [39].”
BackgroundJohnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 43
Kheshtchin, N., & Hadjati, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30643 · Cited by 44
“macrophages, dendritic cells, and tumor cells as well (Noman et al., 2014).”
BackgroundAsija, S., Chatterjee, A., Yadav, S., Chekuri, G., Karulkar, A., Jaiswal, A. K., Goda, J. S., & Purwar, R. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2101647 · Cited by 46
“HIF-1 mediated upregulation of programmed death ligand 1 (PD-L1) is also reported in the literature, which also modulates immunosuppression [76].”
BackgroundThe recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren, R., Xiong, C., Ma, R., Wang, Y., Yue, T., Yu, J., & Shao, B. (2023) · MedComm · doi:10.1002/mco2.323 · Cited by 47
Guo, J., Zhao, W., Xiao, X., Liu, S., Liu, L., La, Z., Lü, L., Li, Z., Li, Z., Xu, M., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.030 · Cited by 60
Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 49
Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter
Hasmim, M., Janji, B., Khaled, M., Noman, M. Z., Louache, F., Bordereaux, D., Abderamane, A., Baud, V., Mami‐Chouaib, F., & Chouaïb, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600981 · Cited by 40
“Luciferase assay was performed as previously described (12).”
MethodSelf-citationMetabolic regulation of suppressive myeloid cells in cancer
Sica, A., Strauss, L., Consonni, F. M., Travelli, C., Genazzani, A. A., & Porta, C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.002 · Cited by 40
Hickey, R., Kulik, L., Nimeiri, H. S., Kalyan, A., Kircher, S. M., Desai, K. R., Riaz, A., Lewandowski, R. J., & Salem, R. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.07.018 · Cited by 41
“The immunosuppressive effects associated with HIF-1a and its effects on MDSCs, however, were successfully limited by PD-L1 inhibition (49).”
BackgroundMitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma
Gooptu, M., Whitaker‐Menezes, D., Sprandio, J. D., Domingo‐Vidal, M., Lin, Z., Uppal, G. K., Gong, J. Z., Fratamico, R., Leiby, B. E., Dulau‐Florea, A., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.002 · Cited by 42
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K., & Secomb, T. W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126044 · Cited by 41
Takahashi, H., Sakakura, K., Arisaka, Y., Tokue, A., Kaira, K., Tada, H., Higuchi, T., Okamoto, A., Tsushima, Y., & Chikamatsu, K. (2019) · Anticancer Research · doi:10.21873/anticanres.13437 · Cited by 42
Liu, T., Wu, H., Qi, J., Qin, C., & Zhu, Q. (2020) · Cancer Medicine · doi:10.1002/cam4.3406 · Cited by 48
Bhattacharya, S., Calar, K., Evans, C. M., Petrasko, M., & de la Puente, P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.01040 · Cited by 43
“Durvalumab is a fully human high affinity immunoglobulin monoclonal antibody that blocks PD-L1 by binding to PD-1 as reflected by its reported IC50 values (PD-1: 0.1nmol/l) and (CD-80: 0.04nmol/l).”
BackgroundInfluentialNavin, I., Lam, M. T., & Parihar, R. (2020) · Cancers · doi:10.3390/cancers12123871 · Cited by 43
“Uncovering the mechanisms behind their reduced activity in solid TMEs will aid the conceptualization of new therapeutic modalities using NK cells.”
BackgroundInfluentialKaira, K., Kuji, I., & Kagamu, H. (2021) · Cancer Imaging · doi:10.1186/s40644-021-00381-y · Cited by 43
“kinase (MAPK) and phosphoinositide-3-kinase (PI3K) signaling pathways [14].”
BackgroundTumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
“PD-L1/PD-1 T-cell suppression [21] IL-10 Tregs induction [22] TGF-β Tregs induction [22] CD40/CD40L Tregs activation [23] Depletion of cystine and cysteine T-cell suppression [24] ROS T-cell suppression [25]”
BackgroundTherapeutic Modification of Hypoxia
Horsman, M. R., Sørensen, B. S., Busk, M., & Siemann, D. W. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.08.014 · Cited by 41
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“Emerging new data demonstrates that hypoxia is involved in the alteration of tumor metabolism and metabolites, pH regulation, and overexpression of several immune checkpoints including macrophage immune checkpoints CD47, PD-L1, and HLA-G [29,30,32,33].”
BackgroundSelf-citationPerspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 46
“Consequently, this prevents lymphocyte extravasation from blood vessels into the TME and facilitates immune exclusion [272,279,280].”
InfluentialErianin: A phytoestrogen with therapeutic potential
Li, G., Zhang, H., Lai, H., Liang, G., Huang, J., Zhao, F., Xie, X., & Peng, C. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1197056 · Cited by 39
Emerging roles of MITF as a crucial regulator of immunity
Lee, A., Lim, J., & Lim, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01175-5 · Cited by 42
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
Ulivi, P., Marisi, G., & Passardi, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8712 · Cited by 42
“Another mechanism through which hypoxia can suppress the immune system is the up-regulation in myeloidderived suppressor cells, dendritic cells and cancer, of the immune checkpoint protein PD-L1, via HIF-1α [86].”
BackgroundMehta, S., Hughes, N. P., Li, S., Jubb, A., Adams, R., Lord, S., Koumakis, L., van Stiphout, R., Padhani, A., Makris, A., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.017 · Cited by 38
“Recently, ProgrammedDeath Ligand 1, PD-L1, not showing significant changes in this study but member of the same CD28/ CTLA4 family of receptors, has been shown to be direct target of HIF1A, and when blocked under hypoxia it enhanced myeloid-derived suppressor cells-mediated T-cell activation (Noman et al., 2014).”
BackgroundZhang, Z., Yi, N., Zhang, T., Zhang, L., Wu, X., Liu, M., Fu, Y., He, S., Jiang, Y., Ding, H., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001471 · Cited by 39
Liu, J., Yang, Y., Wang, H., Wang, B., Zhao, K., Jiang, W., Bai, W., Liu, J., & Yin, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4833-8 · Cited by 41
Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives
Safari, E., Ghorghanlu, S., Ahmadi‐khiavi, H., Mehranfar, S., Rezaei, R., & Motallebnezhad, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27923 · Cited by 41
“, 2014) which can extremely suppress T‐cell‐mediated antitumor activity by binding to PD‐1 receptor expressed on T cells (Gajewski et al., 2013; Noman et al., 2014); (d) secretion of high level of transforming growth factor β (TGF‐β), and interleukin 10 (IL‐10) hindering immune effector cell”
BackgroundInfluentialAge‐dependent hypoxia‐induced PD‐L1 upregulation in patients with obstructive sleep apnoea
Cubillos‐Zapata, C., Balbás‐García, C., Ortiz, J. A., Toledano, V., Torres, M., Almendros, I., Casitas, R., Zamarrón, E., García‐Sánchez, A., Feliú, J., et al. (2019) · Respirology · doi:10.1111/resp.13470 · Cited by 41
Lasso, P., Gomez‐Cadena, A., Urueña, C. P., Donda, A., Martínez-Usatorre, A., Romero, P. J., Barreto, A., & Fiorentino, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584959 · Cited by 44
Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Pramanik, A., & Bhattacharyya, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120755 · Cited by 44
Engineered in vitro tumor models for cell-based immunotherapy
Ando, Y., Mariano, C. F., & Shen, K. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.076 · Cited by 39
Du, M., Yu, T., Zhan, Q., Li, H., Zou, Y., Geng, M., Meng, T., & Xie, Z. (2022) · Cancer Science · doi:10.1111/cas.15468 · Cited by 43
Li, X., Wang, J., Lin, W., Yuan, Q., Lu, Y., Wang, H., Chen, L., Chen, L., Dai, P., Long, H., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01600-1 · Cited by 42
RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy
Sanati, M., Afshari, A. R., Aminyavari, S., Kesharwani, P., Jamialahmadi, T., & Sahebkar, A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104562 · Cited by 42
Long, S., Huang, G., Ouyang, M., Xiao, K., Zhou, H., Hou, A., Li, Z., Zhong, Z., Zhong, D., Wang, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05878-x · Cited by 41
Cellular metabolism hijacked by viruses for immunoevasion: potential antiviral targets
Li, J., Wang, Y., Deng, H., Su, L., & Qiu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228811 · Cited by 49
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 44
Zhang, L., Qiu, M., Wang, R., Li, S., Liu, X., Xu, Q., Xiao, L. X., Jiang, Z., Zhou, X., & Chen, S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202403771 · Cited by 49
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2844-6 · Cited by 42
Oxygen-dependent regulation of immune checkpoint mechanisms
Ohta, A. (2018) · International Immunology · doi:10.1093/intimm/dxy038 · Cited by 39
Koh, Y. W., Lee, S. J., Han, J., Haam, S., Jung, J., & Lee, H. W. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.004 · Cited by 38
Metabolic factors contribute to T‐cell inhibition in the ovarian cancer ascites
Gong, Y., Yang, J., Wang, Y., Xue, L., & Wang, J. (2020) · International Journal of Cancer · doi:10.1002/ijc.32990 · Cited by 46
“Hypoxia also promotes the expression of PD-L1 on the tumor cells andMDSCs, which suppresses T-cell function.(21,22)”
BackgroundRETRACTED: How microRNAs affect the PD-L1 and its synthetic pathway in cancer
Danbaran, G. R., Aslani, S., Sharafkandi, N., Hemmatzadeh, M., Hosseinzadeh, R., Azizi, G., Jadidi‐Niaragh, F., Babaie, F., & Mohammadi, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106594 · Cited by 36
RetractedThe role of myeloid‐derived suppressor cells in gastrointestinal cancer
Cui, C., Lan, P., & Fu, L. (2021) · 癌症:英文版 · doi:10.1002/cac2.12156 · Cited by 42
“[82] demonstrated that MDSCs at the tumor site showed a differential expression of PDL1 as compared with MDSCs from the spleen, which was caused by the HIF-1α expression that selectively upregulated PD-L1 on splenicMDSCs in tumor-bearingmice.”
BackgroundRegulation of PD-L1 Trafficking from Synthesis to Degradation
Lemma, E. Y., Letian, A., Altorki, N. K., & McGraw, T. E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0953 · Cited by 47
Immune cell networking in solid tumors: focus on macrophages and neutrophils
Ceglie, I. D., Carnevale, S., Rigatelli, A., Grieco, G., Molisso, P., & Jaillon, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341390 · Cited by 45
Kong, J. C., Sa’ad, M. A., Vijayan, H. M., Ravichandran, M., Balakrishnan, V., Tham, S. K., & Tye, G. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384039 · Cited by 43
Matsuo, K., Hom, M. S., Moeini, A., Machida, H., Takeshima, N., Roman, L. D., & Sood, A. K. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.019 · Cited by 37
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
Comunanza, V., Corà, D., Orso, F., Consonni, F. M., Middonti, E., Nicolantonio, F. D., Buzdin, A. A., Sica, A., Médico, E., Sangiolo, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505774 · Cited by 40
“Hypoxia also recruits regulatory T-cell (Treg) effectors for tumor tolerance (Facciabene et al, 2011), and up-regulates the expression of programmed death (PD-1) ligand 1 (Noman et al, 2014), which favors the suppressive activity of MDSC (Greenwald et al, 2005).”
BackgroundShu, C., & Li, Q. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102965 · Cited by 41
Non-coding RNAs rewire cancer metabolism networks
Lin, X., Wu, Z., Hu, H., Luo, M., & Song, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.019 · Cited by 37
Zhao, B., Dong, Z., Liu, W., Lou, F., Wang, Q., Hong, H., & Wang, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00865-w · Cited by 38
Osmium–Tellurium Nanozymes for Pentamodal Combinatorial Cancer Therapy
Kang, S., Gil, Y., Yim, G., Min, D., & Jang, H. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c14201 · Cited by 37
Kong, F., Chen, T., Li, X., & Jia, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.737674 · Cited by 39
Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor
Li, X., Chen, L., Peng, X., & Zhan, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911410 · Cited by 43
Wang, Y., Liu, Y., Shu, C., Wan, J., Shan, Y., Zhi, X., Sun, L., Yi, H., Yang, Y., & He, J. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.05.002 · Cited by 37
Zhang, C., Bingxiang, T., Hu, J., Fang, X., Bian, H., Han, J., Hou, C., & Fang, S. (2021) · Bioengineered · doi:10.1080/21655979.2021.1987820 · Cited by 39
“Hypoxia selectively upregulates PD-L1 on MDSCs via HIF-1α and blockade of PD-L1 abrogates MDSCs function [6].”
BackgroundTong, J., Tan, Y., Ouyang, W., & Chang, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00636-5 · Cited by 47
“Additionally, embolization induces a hypoxic microenvironment, resulting in the upregulation of HIF-1α expression, increased expression of PD-L1 on the surface of immune cells and tumor cells [138].”
Chang, C. Y., Tai, J. A., Li, S., Nishikawa, T., & Kaneda, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9743 · Cited by 40
“Moreover, cancers that express PD-L1 in immune cells are likely to be more aggressive than those exclusively expressing PD-L1 in cancer cells [5].”
BackgroundImmune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 40
“An exception is a recent report that links the hypoxic characteristic of the TME to hypoxia-inducible factor-1α-dependent upregulation of PD-L1 on MDSCs, macrophages, and DCs (Noman et al. 2014), extending an earlier study of hypoxia promoting the immune inhibition by MDSCs (Corzo et al.”
BackgroundGargett, T., Christo, S. N., Hercus, T. R., Abbas, M. N., Singhal, N., Lopez, A. F., & Brown, M. P. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.80 · Cited by 36
Qian, X., Zhang, Q., Shao, N., Shan, Z., Cheang, T., Zhang, Z., Su, Q., Wang, S., & Lin, Y. (2019) · Europe PMC (PubMed Central) · Cited by 36
Xie, Z., Ikegami, T., Ago, Y., Okada, N., & Tachibana, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734268 · Cited by 37
“These processes play a key role in the suppression of antitumor T-cell activity.(18,19) VPA alone delayed tumor growth in the EL4 lymphoma-bearing mice and prolonged the survival (Figures 1(a) and 6(b)).”
BackgroundCell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Coleman, M. F., Cozzo, A. J., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Cancers · doi:10.3390/cancers12040852 · Cited by 38
Zuo, H., Hou, Y., Yu, Y., Li, Z., Liu, H., Liu, C., He, J., & Miao, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c18180 · Cited by 36
Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer
Nisar, S., Bhat, A. A., Hashem, S., Yadav, S. K., Rizwan, A., Singh, M. K., Bagga, P., Macha, M. A., Frenneaux, M. P., Reddy, R. D., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02656-7 · Cited by 38
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 43
Bejjani, A. C., & Finn, R. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02605 · Cited by 36
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 38
“The interaction of PD- 1 with its ligand PD-L1 on the surface of tumor cells and other immune cells such as MDSCs, macrophages, DCs induces T-cell exhaustion, anergy and apoptosis.”
BackgroundInfluentialPET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Gao, Y., Wu, C., Chen, X., Ma, L., Zhang, X., Chen, J., Liao, X., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049043 · Cited by 38
Soler, D. C., Young, A. B., Fiessinger, L., Galimberti, F., Debanne, S. M., Groft, S. G., McCormick, T. S., & Cooper, K. D. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.12.036 · Cited by 38
“Whereas control Mo-MDSCs are effective at suppressing CD8 T-cell proliferation (first panel), psoriatic Mo-MDSCs fail to suppress CD8 T-cell proliferation (second panel). www.jidonline.org 801 802 (Kim et al., 2011; Noman et al., 2014).”
BackgroundSalminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.005 · Cited by 36
Labiano, S., Meléndez-Rodríguez, F., Palazón, A., Teijeira, Á., Garasa, S., Etxeberria, I., Aznar, M. Á., Sánchez-Paulete, A. R., Azpilikueta, A., Bolaños, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1283468 · Cited by 35
HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy
Zhang, X., He, C., He, X., Fan, S., Ding, B., Lu, Y., & Xiang, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.026 · Cited by 35
Immunometabolic reprogramming, another cancer hallmark
Kumar, V., & Stewart, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125874 · Cited by 37
Gibellini, L., Borella, R., Santacroce, E., Serattini, E., Boraldi, F., Quaglino, D., Aramini, B., Biasi, S. D., & Cossarizza, A. (2023) · Cancers · doi:10.3390/cancers15133327 · Cited by 37
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers
Shen, L., Chai, Y., Zheng, X., & Xu, X. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08931-2 · Cited by 37
“HIF-1α signalling mediates PD-L1 expression in several immune-suppressive cells [ 65 ].”
BackgroundYan, Q., Liu, J., Liu, Y., Wen, Z., Jin, D., Wang, F., & Gao, L. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05210-6 · Cited by 42
Yu, J. H., Qu, S., Shi, G., Fan, L., Qian, J., Sun, Z., Lu, F., & Han, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c11334 · Cited by 39
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer
Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., Castelli, C., et al. (2016) · Vaccines · doi:10.3390/vaccines4040038 · Cited by 36
“These authors showed that anti-PD-L1 Ab or the depletion of Tregs alone failed to reverse tumor recurrence.”
BackgroundInfluentialBlockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa
Chen, Y., Li, Q., Li, X., Ma, D., Fang, J., Luo, L., Liu, X., Wang, X., Lui, V. W. Y., Xia, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1388484 · Cited by 39
“hypoxia, MDSCs could inhibit T cell function by decreasing the percentage of IFN-gC CD8C and CD4C T cells; whereas blockade of PD-L1 signifcantly increased the percentage of IFN-gC CD8C T and IFN-gC CD4C T cells in spleen and thus abrogated the suppressive activity of MDSCs.(45) Finke et al.”
BackgroundTranslation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 43
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.